Reductions in Lipoprotein Particle Concentration Shown in Patients With Severe (≥500 mg/dL) Hypertriglyceridemia
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE Phase 3 clinical trial are now available electronically through the Journal of Clinical Lipidology and are expected to be published in a future print issue of the journal before the end of 2012.
The publication, titled "AMR101, a Pure EPA Omega-3 Fatty Acid: Effects on Lipoprotein Particle Concentration and Size in Patients with Very High Triglyceride Levels (the MARINE Study)," reports the effects of Vascepa™ (icosapent ethyl) capsules (formerly referred to as AMR101) on lipoprotein particle concentrations and sizes in patients with baseline triglyceride levels ≥500 mg/dL. This publication reported that Vascepa significantly reduced median concentrations of large very-low-density lipoprotein (VLDL), total LDL, small LDL and total high-density lipoprotein (HDL) particles and reduced VLDL particle size in a patient population with TG ≥500 mg/dL. Vascepa did not significantly change the overall sizes of LDL or HDL particles.
The MARINE trial was a Phase 3, multicenter, placebo-controlled, randomized, double-blind, 12-week study. The study enrolled 229 patients and investigated Vascepa as a treatment for severe (TG ≥500 mg/dL) hypertriglyceridemia. The MARINE trial achieved its primary efficacy endpoints as defined in the clinical trial protocol and demonstrated a favorable safety profile.
"Vascepa showed significant improvements in several biomarkers of cardiovascular health," stated Harold Bays, M.D., Medical Director of Louisville Metabolic and Atherosclerosis Research and principal investigator of the MARINE trial. "In this follow-up analysis of the MARINE trial, Vascepa reduced both total and small LDL particle concentration, which is consistent with its known effects in decreasing Apo B and lack of LDL-cholesterol raising in patients with severely high triglyceride levels."
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. VascepaTM (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817
CONTACT: Investor contact information: Stephen D. Schultz Senior Director, Investor Relations and Corporate Communications Amarin Corporation In U.S.: +1 (860) 572-4979 x292 firstname.lastname@example.org Lee M. Stern The Trout Group In U.S.: +1 (646) 378-2922 email@example.com Media contact information: David Schull or Martina Schwarzkopf, Ph.D. Russo Partners In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office) +1 (347) 591-8785 (mobile) firstname.lastname@example.org email@example.com